HC Wainwright Weighs in on Invivyd FY2030 Earnings

Invivyd, Inc. (NASDAQ:IVVD) – HC Wainwright issued their FY2030 earnings per share estimates for Invivyd in a research report issued on Friday, January 23rd. HC Wainwright analyst P. Trucchio forecasts that the company will post earnings of $1.16 per share for the year. HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Invivyd’s current full-year earnings is ($1.64) per share.

Invivyd (NASDAQ:IVVD) last posted its earnings results on Thursday, November 6th. The company reported ($0.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.01). The firm had revenue of $13.13 million for the quarter, compared to the consensus estimate of $12.00 million. Invivyd had a negative net margin of 119.63% and a negative return on equity of 92.97%.

IVVD has been the subject of a number of other reports. Cantor Fitzgerald assumed coverage on shares of Invivyd in a research report on Monday, October 6th. They set an “overweight” rating and a $10.00 price objective for the company. D. Boral Capital reiterated a “hold” rating on shares of Invivyd in a research note on Tuesday, November 25th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Invivyd in a research report on Monday, December 29th. Zacks Research raised shares of Invivyd from a “strong sell” rating to a “hold” rating in a research report on Thursday, November 13th. Finally, BTIG Research reissued a “buy” rating on shares of Invivyd in a report on Wednesday, January 21st. Three research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Invivyd currently has an average rating of “Hold” and an average price target of $8.00.

Invivyd Stock Down 1.0%

Shares of Invivyd stock opened at $2.03 on Monday. Invivyd has a 52 week low of $0.35 and a 52 week high of $3.07. The company has a 50 day moving average price of $2.41 and a 200 day moving average price of $1.65. The firm has a market capitalization of $473.23 million, a P/E ratio of -4.32 and a beta of 0.61.

Insider Buying and Selling

In other Invivyd news, Director Kevin F. Mclaughlin acquired 50,000 shares of Invivyd stock in a transaction on Wednesday, November 19th. The shares were bought at an average price of $2.50 per share, with a total value of $125,000.00. Following the completion of the purchase, the director owned 50,000 shares in the company, valued at $125,000. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. 25.40% of the stock is currently owned by company insiders.

Institutional Trading of Invivyd

Hedge funds have recently added to or reduced their stakes in the business. Invesco Ltd. lifted its position in Invivyd by 190.6% in the 1st quarter. Invesco Ltd. now owns 108,999 shares of the company’s stock valued at $66,000 after acquiring an additional 71,485 shares in the last quarter. AQR Capital Management LLC increased its holdings in Invivyd by 2,051.0% in the 1st quarter. AQR Capital Management LLC now owns 410,711 shares of the company’s stock valued at $249,000 after buying an additional 391,617 shares during the period. Vanguard Personalized Indexing Management LLC boosted its holdings in shares of Invivyd by 238.6% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 39,941 shares of the company’s stock valued at $29,000 after purchasing an additional 28,146 shares in the last quarter. Catalyst Funds Management Pty Ltd bought a new stake in Invivyd during the 2nd quarter worth $27,000. Finally, Marshall Wace LLP bought a new position in Invivyd during the 2nd quarter worth $158,000. Institutional investors and hedge funds own 70.36% of the company’s stock.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.